α-Galactosylceramide potently augments M2e-induced protective immunity against highly pathogenic H5N1 avian influenza virus infection in mice
- PMID: 21839133
- DOI: 10.1016/j.vaccine.2011.07.136
α-Galactosylceramide potently augments M2e-induced protective immunity against highly pathogenic H5N1 avian influenza virus infection in mice
Abstract
A new form of influenza A vaccine that can provide broadly cross-protective immunity is central in developing strategies to prepare for the next global flu pandemic. The ectodomain of the M2 protein (M2e) is an attractive target for developing such a kind of vaccine and several approaches have been proposed to overcome its poor immunogenicity nature. Here, we show change to the poor immunogenic characteristic of this antigen. This study demonstrates that α-galactosylceramide, which is an immunomodulatory glycolipid, can greatly enhance the protective immunity induced by M2e peptide absorbed in alum adjuvant. Mice were fully protected against highly pathogenic H5N1 avian influenza virus infection, exhibiting significantly reduced morbidity and lung viral titer after supplementing with α-galactosylceramide. α-Galactosylceramide simultaneously augmented the IgG1 and IgG2a antibody responses. In addition, mice immune sera showed enhanced abilities in binding to native M2 proteins on virus infected cells. The adjuvant also modulated the cytokine release of mice upon infection, upregulated the expressions of IFN-γ, IL-4 and several proinflammatory cytokines. In conclusion, we believe that M2e-peptide supplemented with α-galactosylceramide in alum adjuvant would be a promising vaccine formulation to combat the next influenza pandemic.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Similar articles
-
Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.Arch Virol. 2017 May;162(5):1251-1260. doi: 10.1007/s00705-017-3230-7. Epub 2017 Jan 24. Arch Virol. 2017. PMID: 28120096
-
An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses.Virol J. 2010 Jan 18;7:9. doi: 10.1186/1743-422X-7-9. Virol J. 2010. PMID: 20082709 Free PMC article.
-
Recombinant baculovirus vaccine containing multiple M2e and adjuvant LTB induces T cell dependent, cross-clade protection against H5N1 influenza virus in mice.Vaccine. 2016 Jan 27;34(5):622-629. doi: 10.1016/j.vaccine.2015.12.039. Epub 2015 Dec 23. Vaccine. 2016. PMID: 26724200
-
Inactivated and adjuvanted whole-virion clade 2.3.4 H5N1 pre-pandemic influenza vaccine possesses broad protective efficacy against infection by heterologous clades of highly pathogenic H5N1 avian influenza virus in mice.Vaccine. 2011 Oct 26;29(46):8330-7. doi: 10.1016/j.vaccine.2011.08.091. Epub 2011 Sep 10. Vaccine. 2011. PMID: 21911027
-
Alum-adjuvanted H5N1 whole virion inactivated vaccine (WIV) induced IgG1 and IgG4 antibody responses in young children.Vaccine. 2012 Dec 14;30(52):7662-6. doi: 10.1016/j.vaccine.2012.10.006. Epub 2012 Oct 24. Vaccine. 2012. PMID: 23102974 Review.
Cited by
-
Ceramide and Related Molecules in Viral Infections.Int J Mol Sci. 2021 May 26;22(11):5676. doi: 10.3390/ijms22115676. Int J Mol Sci. 2021. PMID: 34073578 Free PMC article. Review.
-
LFA-1 Ligation by High-Density ICAM-1 Is Sufficient To Activate IFN-γ Release by Innate T Lymphocytes.J Immunol. 2018 Oct 15;201(8):2452-2461. doi: 10.4049/jimmunol.1800537. Epub 2018 Aug 31. J Immunol. 2018. PMID: 30171164 Free PMC article.
-
Conformationally Restricted Analogues of α-Galactosylceramide as Adjuvant in COVID-19 Subunit Vaccine.ACS Med Chem Lett. 2023 Nov 20;14(12):1647-1655. doi: 10.1021/acsmedchemlett.3c00154. eCollection 2023 Dec 14. ACS Med Chem Lett. 2023. PMID: 38116441 Free PMC article.
-
Geldanamycin Reduces Acute Respiratory Distress Syndrome and Promotes the Survival of Mice Infected with the Highly Virulent H5N1 Influenza Virus.Front Cell Infect Microbiol. 2017 Jun 15;7:267. doi: 10.3389/fcimb.2017.00267. eCollection 2017. Front Cell Infect Microbiol. 2017. PMID: 28664154 Free PMC article.
-
Modulation of Immune Responses to Influenza A Virus Vaccines by Natural Killer T Cells.Front Immunol. 2020 Oct 20;11:2172. doi: 10.3389/fimmu.2020.02172. eCollection 2020. Front Immunol. 2020. PMID: 33193296 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical